| abstract |
The present invention relates to a pre-formulation, which comprises: a) at least one diphospholipid; b) at least one phospholipid; c) at least one biocompatible, organic solvent; d) an alkylammonium EDTA salt; and e ) At least one somatostatin receptor agonist; wherein the pre-formulation has a moisture content ranging from 0 to 1.0 wt%. The present invention further relates to a treatment method comprising administering the aforementioned pre-formulation, a pre-filled dosing device and kit containing the same, alkyl ammonium EDTA salts in reducing lipid components, and / or any active substance contained in the pre-formulation. The use of decomposition. |